3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET
imaging, may help find and diagnose cancer. It may also help doctors predict a patient's
response to treatment and help plan the best treatment.
PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
18 Years and Over
More Inclusion & Exclusion Criteria
- Meets one of the following criteria:
- Histologically confirmed solid tumor or hematologic malignancy
- Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or
- Able to lie still in the PET scanner
- Girth and weight must be suitable to enter the gantry
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
- Not specified
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
- Evaluate the use of 3'-deoxy-3'-[18F] fluorothymidine (FLT) positron emission tomography
(PET) imaging to measure tumor proliferation and the DNA synthetic pathway (thymidine
kinase levels) in patients with cancer.
- Determine the efficacy of FLT PET imaging in detecting lesions and estimating response
OUTLINE: Patients undergo up to four 3'-deoxy-3'-[18F] fluorothymidine positron emission
tomography imaging procedures.
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-1379
Clinical Trials Office - Barbara Ann Karmanos Cancer Institute